Home › Type 2 Diabetes › NCT04783441

Use of CGM in Kidney Transplant Recipients

Continuous Glucose Monitoring (CGM) to Improve Glycemic Control in Kidney Transplant Recipients

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Age 18 or above
2. Received a kidney transplant within the past year with functioning kidney (eGFR \> 30 mL/min
3. Person with Type 2 Diabetes and on insulin
4. Access to home wi-fi connection

Exclusion Criteria:

1. Person with Type 1 Diabetes
2. Patients taking hydroxyurea
3. Patient unable to wear the Dexcom G6 device at all times for any reason
4. Must be able to test blood glucose with meter 4x a day when on blinded CGM.
5. Presence of clinically significant visual or cognitive impairment
6. Illiterate
7. Prisoners
8. Women who are pregnant, who plan to become pregnant during the course of the study, or who are breastfeeding
9. Presence of clinically unstable cardiovascular disease
10. Active malignancy treatment

About the study

The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.

What is being tested

• Dexcom G6 (device)
• Dexcom G6 blinded sensor (device)

Sponsor: University of California, Davis · Participants: 80 · Started: Jun 29, 2021

Contact the study team

• Dahlia Zuidema, PharmD · Phone: 916-734-4009
• Clinical Research Coordinators · Phone: 916-734-4009

Official record on ClinicalTrials.gov — NCT04783441

Locations in the U.S.

Conditions

• Type 2 Diabetes
• Type 1 Diabetes

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.